Drugs & Targets FDA approves Tevimbra + chemo for first-line treatment of gastric and GEJ cancers January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Ryoncil for steroid-refractory acute graft versus host disease in pediatric patients January 10, 2025Vol.51 No.01
Drugs & Targets FDA approves Opdivo and Opdivo Qvantig for subcutaneous injection January 10, 2025Vol.51 No.01
Drugs & Targets FDA grants accelerated approval to encorafenib with cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation January 10, 2025Vol.51 No.01
Drugs & Targets FDA clears IND application for Recursion’s LSD1 inhibitor REC-4539 January 10, 2025Vol.51 No.01
Capitol Hill Don’t confirm RFK Jr. for HHS, 77 Nobel laureates urge the Senate December 13, 2024Vol.50 No.46By Yiqing Wang
Drugs & Targets FDA grants accelerated approval to zenocutuzumab-zbco for NSCLC and pancreatic adenocarcinoma December 06, 2024Vol.50 No.45
Clinical Roundup NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients November 22, 2024Vol.50 No.44
